Immunovant Inc. Common Stock (IMVT)
Stock · NASDAQ · Health Care
$26.73as of 10/16/2026
Price chart
Active signals
IMVT Signal Track Record
How signals performed across all stocks →What IMVT's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 33 | -1.7% | 39% | September 18, 2026 |
| Bollinger Band Breakout | 30 | +1.9% | 53% | August 11, 2026 |
| Bollinger Band Breakdown | 18 | -1.0% | 44% | September 25, 2026 |
| 200-Day Moving Average TouchActive now | 4 | -5.2% | 25% | October 6, 2026 |
| Any 20-session window (baseline) | +1.6% | 54% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About IMVT
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. T…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 315
- Website
- immunovant.com/
Fundamentals
- 1-day range
- $28.7$29.64
- Market cap
- $8.20B
- P/E (trailing)
- —
- P/E (forward)
- -10.44
- EPS (trailing)
- $-2.81
- Dividend yield
- —
- Beta
- 0.91
- Avg. volume
- 1.27M
Forecasts
16 analyst ratings
Immunovant Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- IMVTImmunovant Inc. Common Stock$26.73▼ 2.84%Market cap $8.20BP/E —$16.6$45.42
- PCVXVaxcyte Inc. Common Stock$63.62▼ 2.53%Market cap $8.50BP/E —$39.87$90.75
- QGENQiagen N.V. Common Shares$46.13▼ 0.09%Market cap $8.60BP/E 22.92$32.53$57.82
- IBRXImmunityBio Inc. Common Stock$9.18▼ 8.20%Market cap $7.76BP/E —$1.95$12.43
- KYMRKymera Therapeutics Inc. Common Stock$104.78▼ 3.11%Market cap $8.75BP/E —$55.26$130.05
- RGENRepligen Corporation Common Stock$175.42▼ 4.75%Market cap $9.00BP/E 244.54$100.99$198.87
- KRYSKrystal Biotech Inc. Common Stock$316.58▼ 4.07%Market cap $9.55BP/E 40.85$181.44$382.54
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| IMVT Immunovant Inc. Common Stock | $8.20B | — | $26.73 | ▼ 2.84% | $16.6$45.42 |
| PCVX Vaxcyte Inc. Common Stock | $8.50B | — | $63.62 | ▼ 2.53% | $39.87$90.75 |
| QGEN Qiagen N.V. Common Shares | $8.60B | 22.92 | $46.13 | ▼ 0.09% | $32.53$57.82 |
| IBRX ImmunityBio Inc. Common Stock | $7.76B | — | $9.18 | ▼ 8.20% | $1.95$12.43 |
| KYMR Kymera Therapeutics Inc. Common Stock | $8.75B | — | $104.78 | ▼ 3.11% | $55.26$130.05 |
| RGEN Repligen Corporation Common Stock | $9.00B | 244.54 | $175.42 | ▼ 4.75% | $100.99$198.87 |
| KRYS Krystal Biotech Inc. Common Stock | $9.55B | 40.85 | $316.58 | ▼ 4.07% | $181.44$382.54 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- IMVT, ROIV Stocks Slide As Argenx Sjögren’s Trial Failure Hits Drug ClassYahoo · 10/8/2026
- Argenx, Caribou Biosciences And Other Big Stocks Moving Lower In Thursday’s Pre-Market SessionBenzinga · 10/8/2026
- Why Applied Digital Shares Are Trading Higher; Here Are 20 Stocks Moving PremarketBenzinga · 10/8/2026
- Why Immunovant (IMVT) Is Down 10.3% After Halting IMVT-1402 Development in Cutaneous Lupus – And What's NextYahoo · 9/30/2026
- Immunovant (IMVT) Just Gave Investors Something To Think AboutYahoo · 9/29/2026
- Roivant Sciences Targets LISRAYA Launch, Key Pipeline Readouts in Next 12 MonthsYahoo · 9/28/2026
- Immunovant (IMVT): One Trial Failure Doesn’t Break the Bull CaseYahoo · 9/27/2026
- IMVT Ends Cutaneous Lupus Erythematosus Program, Stock DownYahoo · 9/24/2026
Insider Activity
Insider Actions →- Van Tuyl Christopher · October 7, 2026 · Sale1.3K @ $32.06
- Melanie Gloria · October 7, 2026 · Sale2.2K @ $32.06
- Jay S. Stout · October 7, 2026 · Sale1.6K @ $32.06
- Jay S. Stout · October 7, 2026 · Sale2.2K @ $32.06
- Eric Venker · October 2, 2026 · Sale3.5K @ $34.11
- Eric Venker · October 1, 2026 · Option Exercise92.2K @ $14.46
- Eric Venker · October 1, 2026 · Disposition85.9K @ $33.65
- Van Tuyl Christopher · September 23, 2026 · Sale2.8K @ $36.36
- Atul Pande · August 28, 2026 · Option Exercise1.5K @ $8.43
- Atul Pande · August 28, 2026 · Sale1.5K @ $43.27
- Melanie Gloria · August 20, 2026 · Sale3.1K @ $44.16
- Atul Pande · July 24, 2026 · Option Exercise1.5K @ $8.43
- Atul Pande · July 24, 2026 · Sale1.5K @ $39.8
- Jay S. Stout · July 23, 2026 · Sale2.9K @ $38.69
- Tiago Girao · July 23, 2026 · Sale6.8K @ $38.69
Institutional Ownership
March 31, 2026
- Total shares held
- 108.88M
- Total value held
- $2.60B
- Institutional holders
- 210
- Unknown16.95M
- Unknown11.53M
- Unknown6.57M
- Unknown5.46M
- Unknown5.46M
- Unknown4.54M
- Unknown4.46M
- Unknown3.88M
- Unknown3.62M
- Unknown3.61M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Immunovant (IMVT) releases Q1 2027 earnings call transcript
Immunovant held its Q1 2027 earnings call and made the full transcript available through Benzinga. Management discussed recent results and provided an outlook for the coming quarters. The discussion comes as the stock is in oversold territory, which could heighten market attention to the commentary.
Immunovant (IMVT) releases Q1 2027 earnings call transcript. Immunovant held its Q1 2027 earnings call and made the full transcript available through Benzinga. Management discussed recent results and provided an outlook for the coming quarters. The discussion comes as the stock is in oversold territory, which could heighten market attention to the commentary.